{"id":294351,"date":"2026-06-25T00:00:00","date_gmt":"2026-06-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0033-2024-biopharma-parkinsons-disease-current-treatment-treatment-algorithms-claims-data\/"},"modified":"2026-07-16T11:19:55","modified_gmt":"2026-07-16T11:19:55","slug":"algocg0033-2026-biopharma-parkinsons-disease-current-treatment-treatment-algorithms-claims-data-analysis-parkinsons","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0033-2026-biopharma-parkinsons-disease-current-treatment-treatment-algorithms-claims-data-analysis-parkinsons\/","title":{"rendered":"Parkinson&#8217;s Disease &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Parkinson&#8217;s Disease (US)"},"content":{"rendered":"<p>Parkinson\u2019s disease (<abbr title=\"Parkinson's disease\">PD<\/abbr>) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including dopamine precursors, dopamine agonists, and <abbr title=\"monoamine oxidase B\">MAO-B<\/abbr> inhibitors. Individualized care, a high level of polypharmacy, and frequent medication adjustments as patients progress through lines of therapy are required for <abbr title=\"Parkinson's disease\">PD<\/abbr> treatment. Several new brands have recently entered the competitive <abbr title=\"Parkinson's disease\">PD<\/abbr> therapy market, including AbbVie\u2019s Vyalev (foslevodopa \/ foscarbidopa subcutaneous pump), Amneal\u2019s Crexont (levodopa \/ carbidopa <abbr title=\"extended release\">ER<\/abbr>), and Supernus\u2019s Onapgo (apomorphine subcutaneous pump), and several emerging drugs are poised to launch in 2026 and beyond (e.g., Neuroderm\u2019s ND0612, AbbVie\u2019s tavapadon). A grasp of current market dynamics is crucial for both new and established players vying for a share of this increasingly competitive landscape.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"BulletListStyle1 SCXW173490786 BCX0 round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"Parkinson's disease\">PD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"Parkinson's disease\">PD<\/abbr> patients?<\/li>\n<li>How have Crexont and\u00a0Vyalev been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr title=\"Parkinson's disease\">PD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW173490786 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Acadia, Amneal, Kyowa Kirin, Lundbeck, Merz, Supernus<\/p>\n<p><strong>Key drugs:<\/strong> Duopa, Gocovri, Inbrija, Neupro, Dhivy, Apokyn, Namerzic, Nourianz, Nuplazid, Ongentys, Rytary, Crexont, Vyalev, Onapgo, Xadago<\/p>\n","protected":false},"template":"","class_list":["post-294351","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-therapy-areas-parkinsons-disease","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}